Abstract:Mutations in the COL1A1 and COL1A2 genes, which encode type I collagen, are present in around 85%–90% of osteogenesis imperfecta (OI) patients. Because type I collagen is the principal protein composition of bones, any changes in its gene sequences or synthesis can severely affect bone structure. As a result, skeletal deformity and bone frailty are defining characteristics of OI. Homozygous oim/oim mice are utilized as models of severe progressive type III OI. Bone adapts to external forces by altering its mass and architecture. Previous attempts to leverage the relationship between muscle and bone involved using a soluble activin receptor type IIB‐mFc (sActRIIB‐mFc) fusion protein to lower circulating concentrations of activin A and myostatin. These two proteins are part of the TGF‐β superfamily that regulate muscle and bone function. While this approach resulted in increased muscle masses and enhanced bone properties, adverse effects emerged due to ligand promiscuity, limiting clinical efficacy and obscuring the precise contributions of myostatin and activin A. In this study, we investigated the musculoskeletal and whole‐body metabolism effect of treating 5‐week‐old wildtype (Wt) and oim/oim mice for 11 weeks with either control antibody (Ctrl‐Ab) or monoclonal anti‐activin A antibody (ActA‐Ab), anti‐myostatin antibody (Mstn‐Ab), or a combination of ActA‐Ab and Mstn‐Ab (Combo). We demonstrated that ActA‐Ab treatment minimally impacts muscle mass in oim/oim mice, whereas Mstn‐Ab and Combo treatments substantially increased muscle mass and overall lean mass regardless of genotype and sex. Further, while no improvements in cortical bone microarchitecture were observed with all treatments, minimal improvements in trabecular bone microarchitecture were observed with the Combo treatment in oim/oim mice. Our findings suggest that individual or combinatorial inhibition of myostatin and activin A alone is insufficient to robustly improve femoral biomechanical and microarchitectural properties in severely affected OI mice. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

Activin receptor type 2A (ACVR2A) functions directly in osteoblasts as a negative regulator of bone mass

Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B

Administration of soluble activin receptor 2B increases bone and muscle mass in a mouse model of osteogenesis imperfecta

Acvr1 deletion in osteoblasts impaired mandibular bone mass through compromised osteoblast differentiation and enhanced sRANKL-induced osteoclastogenesis

Blockade of Activin Receptor IIB Protects Arthritis Pathogenesis by Non-Amplification of Activin A-ACVR2B-NOX4 Axis Pathway

Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A

Activin A more prominently regulates muscle mass in primates than does GDF8

Activin A promotes the development of acquired heterotopic ossification and is an effective target for disease attenuation in mice

Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling

Axin2 Controls Bone Remodeling Through the Beta-Catenin-bmp Signaling Pathway in Adult Mice.

Coordinate regulation of Activin and Bone Morphogenetic Protein signaling by a lysosomal trafficking switch

Novel ActRIIB ligand trap increases muscle mass and improves bone geometry in a mouse model of severe osteogenesis imperfecta

v-ATPase V0 subunit d2–deficient mice exhibit impaired osteoclast fusion and increased bone formation

Whole‐Body Metabolism and the Musculoskeletal Impacts of Targeting Activin A and Myostatin in Severe Osteogenesis Imperfecta

Deletion of the Auxiliary α2δ1 Voltage Sensitive Calcium Channel Subunit in Osteocytes and Late-Stage Osteoblasts Impairs Femur Strength and Load-Induced Bone Formation in Male Mice

Vitamin D Receptor in Osteoblasts is a Negative Regulator of Bone Mass Control.

Targeted overexpression of osteoactivin in cells of osteoclastic lineage promotes osteoclastic resorption and bone loss in mice

Activins as Dual Specificity TGF-β Family Molecules: SMAD-Activation via Activin- and BMP-Type 1 Receptors

Notch Signaling in Osteocytes Differentially Regulates Cancellous and Cortical Bone Remodeling

Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage

The Double Mutations of Acvr2aa and Acvr2ba Leads to Muscle Hypertrophy in Zebrafish